Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M7824 plus concurrent chemoradiation versus placebo plus durvalumab after concurrent chemoradiation in unresectable stage III non-small cell lung cancer
NL-OMON52935Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing cCRT + M7824 followed by M7824 with cCRT + placebo followed by durvalumab (2 arms). Primary endpoint: Progression-free survival. Started Jan 2020; status: active, not recruiting.
02
Drugs
bintrafusp alfadurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52935.